secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001493152-23-009382
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics FY2022 net loss narrows to $43.5M; EB-101 BLA submission on track
--------------------------------------------------------------------------------

- Net loss $43.5M ($5.53/share) vs $84.9M ($21.57/share) in FY2021 as expense reductions offset lower revenue.
- Cash of $52.5M at Dec 31, 2022 ($50.9M at Dec 31, 2021); expected to fund operations into Q3 2024.
- Plans to submit BLA for EB-101 (RDEB) to FDA in late Q2/early Q3 2023, based on positive Phase 3 VIITAL results.
- Appointed Dmitriy Grachev as CMO; Madhav Vasanthavada as VP Business Development; Amanda Moore promoted to VP.
- Completed $35M private placement in November 2022 with institutional investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315223009382/0001493152-23-009382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315223009382/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer